GREENVILLE, S.C., May 30 /PRNewswire-FirstCall/ -- Signalife, Inc. announced that physicians outside the United States are excited to have access to the company’s proprietary signal processing technology in the Fidelity 100 ECG System and have ordered the product for use in both practices and clinics.
During a recent patient evaluation, a physician using the Fidelity 100 on a patient indicated that she believed the patient had a variety of heart complications, but prior to use of the Fidelity 100, she had been unable to identify the condition adequately. She immediately ordered the Fidelity 100 for her practice and indicated that many patients in Mexico would benefit from its availability.
“It is exciting to witness the physician delight with Signalife’s technology and to realize how it will impact their patients’ lives. In the US, we have a great variety of diagnostic tools for physicians use, but in Mexico, the ECG is considered a valuable diagnostic tool that is well utilized by physicians. Even the subtleties of the device and its signal processing capabilities are highly valued and recognized,” stated Pam Bunes, CEO of Signalife, Inc. “We anticipate great success in Mexico and the rest of Latin America as we continue our sales effort in those markets.”
About Signalife
Signalife, Inc. is a life sciences company focused on the monitoring and detection of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices that simplify and reduce the costs of diagnostic testing and patient monitoring in an ambulatory setting.
Signalife is publicly traded on the American Stock Exchange under the symbol SGN. The website for the company is http://www.Signalife.com. Clear Data. Trusted Results.
Caution Regarding Forward-Looking Statements
Statements in this release that are not strictly historical are “forward- looking” statements. Forward-looking statements involve known and unknown risks, which may cause Signalife’s actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating Signalife’s technology, failure to obtain federal or state regulatory approvals governing heart monitoring and other biomedical devices incorporating Signalife’s technology, inability to obtain physician, patient or insurance acceptance for heart monitoring and other biomedical devices incorporating Signalife’s technology, and the unavailability of financing to complete management’s plans and objectives, including the development of heart monitoring and other biomedical devices incorporating Signalife’s technology. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Signalife’s filings with the Securities and Exchange Commission.
Signalife, Inc.
CONTACT: Kevin Kading of Signalife, Inc., +1-212-918-4606
Web site: http://www.Signalife.com//
